腎細胞癌市場：KOL 洞察

本報告考察了全球腎細胞癌市場，並提供了市場概述，包括已上市療法、管道趨勢和未來前景。

目錄

執行摘要

處理演算法

研究目的

免疫治療

• 市售治療方法
  • Opdivo (nivolumab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Bavencio (avelumab; Merck KGaA)
  • Imfinzi (durvalumab; AstraZeneca)

VEGF抑制劑

• 市售治療方法
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Lenvima/Kisplyx (lenvatinib; Eisai/Merck & Co.)
  • Inlyta (axitinib; Pfizer)
  • Fotivda (tivozanib; AVEO Oncology)
  • Sutent (sunitinib; Pfizer)
  • Votrient (pazopanib; Novartis)

其他作用機轉

• 市售治療方法
  • Welireg (belzutifan; Merck & Co.)
• 管道療法
  • Abexinostat (Xynomic Pharmaceuticals)
  • Savolitinib (AstraZeneca/HUTCHMED)
  • Epacadostat (Incyte)
• Tiragolumab (Roche)
• Zanzalintinib (Exelixis)

未來的治療範例

附錄

Gain insights from leading KOLs on the latest trends in RCC treatment, including the steady use of Opdivo/Yervoy, the rising role of Keytruda, and the broad efficacy of Cabometyx. Discover how clinical trials and patient characteristics are shaping the future of RCC therapy.

Key brands covered in this report:

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Cabometyx (cabozantinib)
• Imfinzi (durvalumab)
• Tecentriq (atezolizumab)
• Welireg (belzutifan)

Key questions answered:

• What are the preferred therapies for RCC, and what factors influence these choices?
• What is the expert consensus on approved RCC treatments like Opdivo, Keytruda, Cabometyx and Lenvima/Kisplyx?
• What are the most promising late-stage pipeline drugs or classes and other novel approaches for RCC?
• What must new pipeline products show in terms of safety and efficacy to gain regulatory approval and compete with current leaders, and what are their chances?
• How do patient characteristics (risk group, performance status, co-morbidities) influence RCC treatment decisions, and how will emerging treatments fit into these specific populations?
• Which advanced clinical trials have the greatest potential to change prescribing habits, and how could their outcomes impact future practice?
• How is the RCC treatment landscape expected to evolve for each patient category and treatment line in the coming years?

Companies:

Novartis, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Incyte, Exelixis, Ipsen, AVEO Oncology, Xynomic Pharma, Hutchmed.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Immunotherapy

• Marketed therapies
  • Opdivo (nivolumab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Bavencio (avelumab; Merck KGaA)
  • Imfinzi (durvalumab; AstraZeneca)

VEGF inhibitors

• Marketed therapies
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Lenvima/Kisplyx (lenvatinib; Eisai/Merck & Co.)
  • Inlyta (axitinib; Pfizer)
  • Fotivda (tivozanib; AVEO Oncology)
  • Sutent (sunitinib; Pfizer)
  • Votrient (pazopanib; Novartis)

Other mechanisms of action

• Marketed therapies
  • Welireg (belzutifan; Merck & Co.)
• Pipeline therapies
  • Abexinostat (Xynomic Pharmaceuticals)
  • Savolitinib (AstraZeneca/HUTCHMED)
  • Epacadostat (Incyte)
• Tiragolumab (Roche)
  • Key insights summary
• Zanzalintinib (Exelixis)
  • Key insights summary

Future treatment paradigm

• Key insights summary

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe